Yezan Munther Haddadin - Mar 28, 2024 Form 4 Insider Report for Outlook Therapeutics, Inc. (OTLK)

Role: Director
Signature: /s/ Lawrence Kenyon, Attorney-in-Fact
Stock symbol: OTLK
Transactions as of: Mar 28, 2024
Transactions value $: $22,242
Form type: 4
Date filed: 3/29/2024, 10:39 AM
Previous filing: Mar 8, 2024
Next filing: Oct 3, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OTLK	Common Stock	Purchase	$22.2K	+1.88K	+59.42%	$11.82^*	5.05K	Mar 28, 2024	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $11.78 to $11.8249 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2	Reflects the Issuer's 1-for-20 reverse stock split effected on March 13, 2024.

Content

The price reported in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $11.78 to $11.8249 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Reflects the Issuer's 1-for-20 reverse stock split effected on March 13, 2024.